Citi resumed its coverage of SXC Health Solutions SXCI on Friday after the company completed its merger with Catalyst Health Solutions effective July 2. Citi raised its SXC Health Solutions price target from $84 to $120 and reiterated its Buy rating.
In the report, Citi stated, "We continue to believe SXCI's unique business model that includes Healthcare IT, combined with CHSI's centers of excellence, will resonate with mid-size and increasingly Fortune 500 clients."
Shares of SXC Health Solutions were trading at $96.43 at the time of posting, up 0.06% from Thursday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in